Lord, Abbett & Co
KITE

Lord, Abbett & Co’s Kite Pharma, Inc. KITE Stock Holding History

Lord, Abbett & Co’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-130,498
Closed -$13.5M – 968
2017
Q2 		$13.5M Sell
130,498
-130,879
-50% -$10.7M 0.04% 551
2017
Q1 		$20.5M Buy
+261,377
New +$16.2M 0.06% 436
2016
Q1 		– Sell
-144,611
Closed -$8.91M – 1000
2015
Q4 		$8.91M Buy
+144,611
New +$10.2M 0.03% 624
2015
Q2 		– Sell
-52,613
Closed -$3.04M – 1019
2015
Q1 		$3.04M Sell
52,613
-22,856
-30% -$1.53M 0.01% 807
2014
Q4 		$4.35M Buy
+75,469
New +$3.18M 0.01% 755

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co's KITE Position: Q3 2017 in Review

Lord, Abbett & Co sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 130,498 shares — an estimated $13.5M sold.

Lord, Abbett & Co first reported a position in KITE in Q4 2014 and held it in 5 quarters. The position peaked at $20.5M in Q1 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Lord, Abbett & Co reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 130,498 Kite Pharma, Inc. shares in Q3 2017, an estimated $13.5M.
  • Lord, Abbett & Co first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 5 quarters.
  • Lord, Abbett & Co's Kite Pharma, Inc. position peaked at $20.5M in Q1 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Lord, Abbett & Co's 13F filing for Q3 2017, filed 14 Nov 2017.